Lyell Immunopharma (LYEL) Enterprise Value (2019 - 2026)
Lyell Immunopharma recorded quarterly Enterprise Value of -$254.0 million in Q1 2026, down 2.75% quarter-over-quarter from -$247.2 million in Q4 2025, and up 15.66% year-over-year from -$219.6 million in Q1 2025.
Lyell Immunopharma's Enterprise Value history runs 8 years deep, the most recent figure standing at -$254.0 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 15.66% year-over-year to -$254.0 million; the TTM figure through Mar 2026 stood at -$254.0 million (up 15.66% YoY), while the FY2025 annual figure was -$247.2 million, up 33.28% from the prior year.
- Enterprise Value came in at -$254.0 million for Q1 2026 at Lyell Immunopharma, down from -$247.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$247.2 million in Q4 2025 to a low of -$655.6 million in Q2 2022.
- A 5-year average of -$477.4 million and a median of -$526.3 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value tumbled 151.22% in 2022 and surged 43.64% in 2025, its largest moves.
- Lyell Immunopharma's Enterprise Value stood at -$640.2 million in 2022, then rose by 14.67% to -$546.2 million in 2023, then surged by 32.17% to -$370.5 million in 2024, then jumped by 33.28% to -$247.2 million in 2025, then decreased by 2.75% to -$254.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$254.0 million, -$247.2 million, and -$319.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Lyell Immunopharma | 373.31 Mn | 373.31 Mn | - | -254.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -254.02 Mn |
| Dec 31, 2025 | -247.22 Mn |
| Sep 30, 2025 | -319.62 Mn |
| Jun 30, 2025 | -276.79 Mn |
| Mar 31, 2025 | -301.18 Mn |
| Dec 31, 2024 | -370.53 Mn |
| Sep 30, 2024 | -440.55 Mn |
| Jun 30, 2024 | -491.12 Mn |
| Mar 31, 2024 | -526.30 Mn |
| Dec 31, 2023 | -546.22 Mn |
| Sep 30, 2023 | -575.43 Mn |
| Jun 30, 2023 | -595.75 Mn |
| Mar 31, 2023 | -612.77 Mn |
| Dec 31, 2022 | -640.15 Mn |
| Sep 30, 2022 | -648.13 Mn |
| Jun 30, 2022 | -655.56 Mn |
| Mar 31, 2022 | -613.91 Mn |
| Dec 31, 2021 | -614.79 Mn |
| Sep 30, 2021 | -618.92 Mn |
| Jun 30, 2021 | -824.52 Mn |
| Mar 31, 2021 | -244.37 Mn |
| Dec 31, 2020 | -612.62 Mn |
| Sep 30, 2020 | -134.41 Mn |
| Jun 30, 2020 | -245.95 Mn |
| Dec 31, 2019 | -96.67 Mn |